Ciplas 3QFY16 numbers took a hit owing to several factors, including (1) One-time impact of change in distribution policy in the domestic business, (2) Earlier-than-expected erosion in Nexium, (3) Increase in R&D; spend, (4) Currency devaluation in South Africa, (5) Decline in API sales and (6) Increased spending on consumer and biologics business.